TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: change in WPPSI-III Processing Speed Quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in scaled scores of Nepsy II attention and executive function domain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Th2 Cytokines (IL-13)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Th2 Cytokines (IL-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Kidney Allograft Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Graft Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Pain on the Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Wilson's disease rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total intake by weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total intake by energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radiotherapy volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiotherapy dose distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MR radiomics extracted features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NHPs (Non-Hospitalized Patients) measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: β-cell function (first-phase insulin secretion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Peak Plasma Concentration (CMAX) of Amoxicillin-Clavulanic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of Amoxicillin-Clavulanic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in blood parameters (Hemoglobin, leucocytes, trombocytes, serum sodium, potassium, creatinine, phosphatase, ALAT, ASAT, bilirubin, CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dose limiting toxicity (grade 3 or more)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to evaluation of breast cancer or treatment-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Men Reporting Conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Volume of Daily Consumption of Study Product
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Labor progress variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of difficult airway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sound Detection Via Pure-tone Threshold Audiometry (PTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech Perception Following Cochlear Implantation Assessed by Consonant-Nucleus-Consonant (CNC) Word Recognition Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean ratio of rivaroxaban AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Active Range of Motion of Hallux Extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cognitive domain factor score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Location Learning score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to maximum measured concentration of the analyte in plasma (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wear of teeth and materials of restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of AAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with neutralizing HAHA antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 2-point shift in treated area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pain level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Vasospasm detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resting SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in immune cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma levels of prostaglandin E2 (PGE2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reorientation (TRO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical short- and long-term results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of non-diagnostic tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lymphoblast percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference between software calculation and dosimetry film measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: difference in serious adverse event rates
Endpoint domain: Adverse events/effects
Primary endpoint: Diffusion Tensor Imaging on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Systemic morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of Docetaxel-PNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase II dose of Docetaxel-PNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of peptic ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bleeding rate of peptic ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Plasma Concentration (AUCt) of Guaifenesin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until recurrence of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left ventricular pressure volume area (PVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic pressure volume area (PVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of blastocyst with genomic DNA present
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of Upper Limbs scale (PUL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HER2 positive circulating tumor cells (CTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: asthma episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ophthalmological Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychophysical Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Adjusted Symptom Score (AAdSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Myoelectricity of genioglossus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pharyngeal current sensory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma betatrophin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Grades III/IV Acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Disease Control Rate (DCR) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Increase in Visual Acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients harvested with ≥ 6 million CD34+ cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Teamwork Event Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of the perforator flap
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from Baseline Diabetic neuropathy symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline of the Fuzzy classification of the diabetic neuropathy severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Social Skills Rating System (Parent Report)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Percentage of subjects consuming at least 90% of dietary resistant starch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Asthma Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumococcal antibody titers increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of leaflet thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Beta-cell Function; AIRg - Acute Insulin Response to Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin Sensitivity (SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adherence to physical exercise programs
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nine Hole Peg Test (9HPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity against vaccine strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effectiveness of pleural ultrasound in diagnosing parapneumonic effusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients with minimum residual disease (MRD) < 10-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Predictive value of negative sentinel lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Neuroimaging Positron Emission Tomography for Amyloid Biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuroimaging Positron Emission Tomography for Tau Biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neuropsychiatric and Neurocognitive Tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pneumococcal Serotype Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: obsessive-compulsive symptom
Endpoint domain: Adverse events/effects
Primary endpoint: reinforcement sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of active gastrointestinal disorder/dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of AE leading to discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal hematology parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Genetic counseling uptake
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in amount of early macular degeneration signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma lutein and zeaxanthin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK as measured by Cmax, Tmax, AUC, residual area, T1/2, CL and V
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local tolerability as measured by signs and symptoms of inflammation
Endpoint domain: Adverse events/effects
Primary endpoint: Safety as measured by Adverse events, clinical chemistry, hematology, urinalysis, physical examination, ECG and BP
Endpoint domain: Adverse events/effects
Primary endpoint: Effect of treatment on prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in posttraumatic stress symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in State Anxiety Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Posterior Cervical Muscle Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of LY900020
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration (Cmax) of LY900020
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appendicular lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Relapse to Smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Abstinent and Nonabstinent Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability assessed using the modified Rankin Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Adverse event differences
Endpoint domain: Adverse events/effects
Primary endpoint: Lesion volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Laboratory Abnormalities in Specific Liver Tests
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Laboratory Results of Worst CTC Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Hamilton Anxiety Rating Scale (HAM-A) Total Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Log CAC Volume Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma levels of Capecitabine and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Minute Walking Distance (MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue monitoring
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Steep ramp test (SRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Esthetic Properties
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Functional Properties
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Biological Properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with a positive SARS-CoV-2 PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ghrelin levels in Gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of creatine kinase (CK)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voltage difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stimulus current
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sEEG voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metabolic disposition to obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction of pulmonary inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Medication dosage errors
Endpoint domain: Adverse events/effects
Primary endpoint: Residual AR binding sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of children with adequate parasitological clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in plaque composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum percentage changes in mean blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement of knowledge about the procedure
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Tumor oxygenation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in WOMAC osteoarthritis index score at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in WOMAC osteoarthritis index score at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall Driving Safety Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spot Urinary Oxalate to Creatinine Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Adipocytokine levels in synovial fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of prophylaxis administered within recommended timeframes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal Incontinence Quality of Life (FIQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Static Forward Head Posture (sFHP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Dynamic Forward Head Posture (dFHP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pruritus degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in velocity of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in step length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and efficacy of HyperAcute Breast cancer cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Global Performance on Computerized Attentional Control Tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Mind-Wandering During Attentional Control Tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Qualitative result of molecular tests for SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum EPO Levels Above Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in interhemispheric desynchronization of delta waves (IHDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response rate (ORR) at recommended dose
Endpoint domain: Physiological/clinical
Primary endpoint: Frequency of insulin omission/non-adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiple Gestation Rate
Endpoint domain: Mortality/survival
Primary endpoint: Lipolysis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: modified Children's Hospital of Eastern Ontario Pain Scale (mCHEOPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bacterial colonization of subglottic secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Accuracy of endometrial thickness and pattern in predicting endometrial hyperplasia and cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Arterial blood gas changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative dosage of sodium bicarbonate injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Chlorine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of endoscopic cryotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of endoscopic cryotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of intolerance
Endpoint domain: Adverse events/effects